HRMY NASDAQ
Harmony Biosciences Holdings, Inc.
1W: -1.9%
1M: -5.2%
3M: +5.8%
YTD: +1.5%
1Y: +25.4%
3Y: +88.5%
5Y: -9.4%
$37.95
+1.12 (+3.04%)
Weekly Expected Move ±5.1%
$32
$34
$36
$38
$40
Credit Risk of going bust: lower than 74% of companies Debt: 6.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.26 (down 99.3%), Harmony Biosciences Holdings, Inc. would be worth roughly what it owes.
Total debt $154.0M against a stock market value of $2.21B.
Distance to default 8.34 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $87.0M (short-term plus half of long-term), stock volatility 40.3%; Altman Z'' 7.45. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.26 (down 99.3%), Harmony Biosciences Holdings, Inc. would be worth roughly what it owes.
Total debt $154.0M against a stock market value of $2.21B.
Distance to default 8.34 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $87.0M (short-term plus half of long-term), stock volatility 40.3%; Altman Z'' 7.45. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships6
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2023-08-14
Earliest Filing
2023-10-11
Latest Filing
target: 3
acquirer: 2
partner: 1
Counterparties (Filed by HRMY)
6 relationshipsCompanies named in HRMY's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Zynerba Pharmaceuticals, Inc. | ZYN | target | Target company acquired in a merger transaction. | 2023-10-11 | View |
| Xylophone Acquisition Corp. | — | acquirer | Special purpose acquisition company that merged with Zynerba. | 2023-10-11 | View |
| Xylophone Acquisition Corp. | — | partner | Wholly owned subsidiary of Harmony Biosciences Holdings, Inc. entering Merger Agreement | 2023-09-14 | View |
| Zynerba Pharmaceuticals, Inc. | — | target | Counterparty in Merger Agreement with Harmony Biosciences Holdings, Inc. | 2023-09-14 | View |
| Xylophone Acquisition Corp. | — | acquirer | Wholly owned subsidiary of Harmony Biosciences Holdings, Inc. entering into a merger agreement with Zynerba Pharmaceutic | 2023-08-14 | View |
| Zynerba Pharmaceuticals, Inc. | — | target | Target company in a merger agreement with Harmony Biosciences Holdings, Inc. and its subsidiary Xylophone Acquisition Co | 2023-08-14 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-13 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-08-04 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-07-16 | Earnings Release; Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-05-14 | Shareholder Vote | View | |
| 2026-05-07 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-04-14 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-04-02 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-02-24 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-11-04 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-10-23 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-24 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-05 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-06-11 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-06-05 | Other Events; Financial Statements and Exhibits | View | |
| 2025-05-15 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-06 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-04-03 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-03-24 | Departure/Election of Directors; Appointment of Officers; Other Events; Financial Statements and Exh | View | |
| 2025-02-25 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR